Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)

被引：0
|
作者：
Braun, Thorsten [1 ]
Raffoux, Emmanuel [2 ]
Prebet, Thomas [3 ]
Brechignac, Sabine [1 ]
Stamatoullas, Aspasia [4 ]
Dreyfus, Francois [5 ]
Hebibi, Zehaira [6 ]
Ades, Lionel [1 ]
Vey, Norbert [3 ]
Dombret, Herve [2 ]
Fenaux, Pierre [1 ]
Cardin, Claude [1 ]
机构：
[1] Univ Paris 13, Avicenne Hosp, APHP, Dept Hematol, Bobigny, France
[2] Univ Paris 07, St Louis Hosp, APHP, Dept Hematol, Paris, France
[3] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[4] Ctr Henri Becquerel, Dept Hematol, F-76038 Rouen, France
[5] Univ Paris 05, Cochin Hosp, APHP, Paris, France
[6] GFM, Bobigny, France
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：279 / 280
页数：2
相关论文
共 15 条
  • [1] Escalating doses of clofarabine (CLO) for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia post-MDS (sAML) failing azacitidine (AZA)
    Braun, T.
    Raffoux, E.
    Prebet, T.
    Stamatoullas, A.
    Brechignac, S.
    Dreyfus, F.
    Samey, B.
    Ades, L.
    Vey, N.
    Dombret, H.
    Fenaux, P.
    Gardin, C.
    LEUKEMIA RESEARCH, 2013, 37 : S149 - S149
  • [2] Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
    Cortes, J. E.
    Feldman, E. J.
    Douer, D.
    Raza, A.
    Fruchtman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
  • [4] Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Kadia, Tapan M.
    Jabbour, Elias
    Pemmaraju, Naveen
    Faderl, Stefan
    Borthakur, Gautam
    Thomas, Deborah A.
    Daver, Naval Guastad
    Ravandi, Farhad
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute myeloid leukemia in patients with significant comorbidities
    Butera, J.
    Winer, E.
    Wang, C.
    Castillo, J. J.
    Thomas, A. G.
    Safran, H.
    Mega, A. E.
    Colvin, G. A.
    Rathore, B.
    Quesenberry, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Cortes, J.
    O'Connell, A.
    Shaik, M. N.
    Cesari, R.
    Abbattista, A.
    Woolfson, A.
    Pollyea, D.
    Savona, M.
    HAEMATOLOGICA, 2014, 99 : 33 - 33
  • [7] Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
    Guillaume, Thierry
    Malard, Florent
    Magro, Leonardo
    Labopin, Myriam
    Tabrizi, Reza
    Borel, Cecile
    Chevallier, Patrice
    Vigouroux, Stephane
    Peterlin, Pierre
    Garnier, Alice
    Rubio, Marie-Therese
    Huynh, Anne
    Milpied, Noel
    Moreau, Philippe
    Gaugler, Beatrice
    Yakoub-Agha, Ibrahim
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2019, 54 (11) : 1815 - 1826
  • [8] Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
    Thierry Guillaume
    Florent Malard
    Leonardo Magro
    Myriam Labopin
    Reza Tabrizi
    Cécile Borel
    Patrice Chevallier
    Stéphane Vigouroux
    Pierre Peterlin
    Alice Garnier
    Marie-Thérèse Rubio
    Anne Huynh
    Noël Milpied
    Philippe Moreau
    Béatrice Gaugler
    Ibrahim Yakoub-Agha
    Mohamad Mohty
    Bone Marrow Transplantation, 2019, 54 : 1815 - 1826
  • [9] Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib
    Heidel, Florian
    Cortes, Jorge
    Ruecker, Frank G.
    Aulitzky, Walter
    Letvak, Laurie
    Kindler, Thomas
    Huber, Christoph
    Doehner, Hartmut
    Kantarjian, Hagop
    Fischer, Thomas
    CANCER, 2007, 109 (05) : 907 - 914
  • [10] A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60years of age
    Buckley, Sarah A.
    Mawad, Raya
    Gooley, Ted A.
    Becker, Pamela S.
    Sandhu, Vicky
    Hendrie, Paul
    Scott, Bart L.
    Wood, Brent L.
    Walter, Roland B.
    Smith, Kelly
    Dean, Carol
    Estey, Elihu H.
    Pagel, John M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (03) : 349 - 355
12